Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab tesirine in relapsed or refractory DLBCL (China, Phase II)
CTR20211724Phase 2Terminated
- Sponsor
- Henan Lingrui Pharmaceutical Co., Ltd.
- Start
- Jul 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL), sponsored by Henan Lingrui Pharmaceutical Co., Ltd.. Started Jul 2021; status: terminated.
02
Drugs
loncastuximab tesirine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20211724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211724.